NL-OMON40972
招募中
不适用
A clinical pathway for older prostate cancer patients - Clinical Pathway Prostate Cancer
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- malignancy of the prostate
- 发起方
- IVE
- 入组人数
- 20
- 状态
- 招募中
- 最后更新
- 2年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- •Diagnosis of prostate cancer
- •Age at least 65 and at least one chronic disease (of a list of 30 diseases of the RIVM);Specific criteria for the different treatment options:
- •After radical prostatectomy inclusion 1 year after operation if:
- •PSA \< 0,1
- •No other active treatment by urologist (for example erectile dysfunction or incontinence)
- •After radiotherapy (in\- or external) inclusion 1 year after radiotherapy if:
- •PSA declining
- •No other active treatment by urologist (for example erectile dysfunction or incontinence)
- •Watchful waiting inclusion 6 months after start watchful waiting if:
排除标准
- •\- In active medical treatment
- •\- After\-care by GP not medically safe
- •\- in the normal situation the patient would be checked by the urologist for at least one year
结局指标
主要结局
未指定
相似试验
已完成
不适用
Patient involvement in prostate cancer treatment decisionsProstate cancerCancerISRCTN97145188Dutch Cancer Society (The Netherlands)300
招募中
不适用
The safety and efficacy of Irreversible Electroporation for the ablation of prostate cancer assessed by procedural related side effects and post prostatectomy histology: A pilot studyProstate cancerCancer - ProstateACTRN12612000523808Flack Trustees6
招募中
不适用
Clinical study of prostate cancer dagnositic makers using genetic polymorphismsProstate cancerJPRN-UMIN000019278Kyoto University2,000
招募中
1 期
Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/3 TrialProstate cancerTherapeutic area: Diseases [C] - Neoplasms [C04]CTIS2022-501551-90-00Gasthuiszusters Antwerpen493
已完成
不适用
Transmurale zorg Prostaatkanker, van diagnose tot en met nazorgProstate cancer, transmural care, decision aid, SDM, Follow-up care, Substitution, Family doctors or General practitioners, Prostaatkanker, Keuzehulp, Samenwerking tussen eerste lijn en tweede lijn.NL-OMON22953Initiator: Catharina Wilhelmina Hospital (CWZ)NijmegenPrimary Sponsor/Performer: Radboud University Nijmegen Medical centerOther performers: CWZ in Nijmegen, Maashospital Pantein in Boxmeer200